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RESEARCH Open Access
Treatment failure and hospital readmissions
in severe COPD exacerbations treated with
azithromycin versus placebo – a post-hoc
analysis of the BACE randomized controlled
trial
Kristina Vermeersch1,2 , Ann Belmans3,4, Kris Bogaerts3,4, Iwein Gyselinck1, Nina Cardinaels1, Maria Gabrovska5,
Joseph Aumann6, Ingel K. Demedts7, Jean-Louis Corhay8, Eric Marchand9,10, Hans Slabbynck11,
Christel Haenebalcke12, Stefanie Vermeersch13, Geert M. Verleden1,2, Thierry Troosters1,14, Vincent Ninane5,
Guy G. Brusselle13, Wim Janssens1,2* and On behalf of the BACE trial investigators
Abstract
Background: In the BACE trial, a 3-month (3m) intervention with azithromycin, initiated at the onset of an infectious
COPD exacerbation requiring hospitalization, decreased the rate of a first treatment failure (TF); the composite of
treatment intensification (TI), step-up in hospital care (SH) and mortality.
Objectives: (1) To investigate the intervention’s effect on recurrent events, and (2) to identify clinical subgroups most
likely to benefit, determined from the incidence rate of TF and hospital readmissions.
Methods: Enrolment criteria included the diagnosis of COPD, a smoking history of ≥10 pack-years and≥ 1 exacerbation
in the previous year. Rate ratio (RR) calculations, subgroup analyses and modelling of continuous variables using splines
were based on a Poisson regression model, adjusted for exposure time.
Results: Azithromycin significantly reduced TF by 24% within 3 m (RR = 0.76, 95%CI:0.59;0.97, p = 0.031) through a
50% reduction in SH (RR = 0.50, 95%CI:0.30;0.81, p = 0.006), which comprised of a 53% reduction in hospital
readmissions (RR = 0.47, 95%CI:0.27;0.80; p = 0.007). A significant interaction between the intervention, CRP and
blood eosinophil count at hospital admission was found, with azithromycin significantly reducing hospital
readmissions in patients with high CRP (> 50 mg/L, RR = 0.18, 95%CI:0.05;0.60, p = 0.005), or low blood eosinophil
count (<300cells/μL, RR = 0.33, 95%CI:0.17;0.64, p = 0.001). No differences were observed in treatment response by
age, FEV1, CRP or blood eosinophil count in continuous analyses.
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Conclusions: This post-hoc analysis of the BACE trial shows that azithromycin initiated at the onset of an infectious
COPD exacerbation requiring hospitalization reduces the incidence rate of TF within 3 m by preventing hospital
readmissions. In patients with high CRP or low blood eosinophil count at admission this treatment effect was more
pronounced, suggesting a potential role for these biomarkers in guiding azithromycin therapy.
Trial registration: ClinicalTrials.gov number. NCT02135354.
Keywords: Recurrent event, Readmission, Macrolide, CRP, Eosinophil count
Key questions
What is the key question?
A 3-month intervention with low-dose azithromycin, ini-
tiated at the onset of an infectious COPD exacerbation
requiring hospitalization, reduced treatment failure (a
novel composite primary endpoint) within 3 months of
hospital admission in the BACE trial. The intervention’s
effect on the individual exclusive subcomponents of
treatment failure and its effect in pre-specified clinical
subgroups are not known.
What is the bottom line?
This comprehensive recurrent-event post-hoc analysis
demonstrates that azithromycin significantly reduces the
rate of treatment failure within 3months of hospitalization
for an infectious COPD exacerbation by preventing subse-
quent hospital readmissions with 53%. This treatment
benefit is most pronounced in patients with either high
CRP (> 50mg/L) or low blood eosinophil count (< 300
cells/μL) at hospital admission.
Why read on?
Azithromycin may be a promising intervention to reduce
hospital readmissions in a COPD subgroup at high risk.
The present findings also suggest a potential role for
CRP and blood eosinophil count in guiding azithromycin
therapy.
Introduction
In the field of chronic obstructive pulmonary disease
(COPD), acute exacerbations (AECOPD) are considered
the most important determinants of a patient’s health
status [1–3]. They are characterized by an acute wors-
ening of respiratory symptoms that necessitate add-
itional therapy, based on which they are classified as
mild (treated with short-acting bronchodilators only),
moderate (requiring systemic corticosteroids and/or
antibiotics) or severe (requiring hospitalization) [4].
Hospital readmissions after an initial hospitalization for
an exacerbation (‘index event’) are associated with sig-
nificant morbidity, mortality and high resource
utilization [5], especially within the first 3 months after
hospital discharge [6].
We recently reported the results of the Belgian trial with
Azithromycin for acute COPD Exacerbations requiring
hospitalization (BACE, NCT02135354) [7]. The BACE
trial was an investigator-initiated randomized placebo-
controlled trial (RCT) comparing azithromycin (500mg
once a day for 3 days and subsequently administered for 3
months at 250mg every 2 days) with placebo on a novel
composite primary endpoint, treatment failure (TF).
Though formally negative on the primary endpoint (p =
0.0526), the applied time-to-first event analyses of its 3
subcomponents revealed that the reduction in TF rate
within 3months of hospital admission was mainly driven
by a significant decrease of treatment intensification with
systemic corticosteroids and/or antibiotics (TI), as well as
step-up in hospital care (SH) for respiratory reasons, while
no difference was observed for all-cause mortality. The
main analyses, however, limit our understanding to
‘whether’ and ‘when’ a first TF, or one of its subcompo-
nents, occurred [8].
In the present study, we aimed to investigate the inter-
vention’s effect on recurrent events, with a particular
focus on hospital readmissions. Based on a number of
pre-specified baseline patient characteristics, we add-
itionally aimed to identify clinical subgroups most likely
to benefit, determined from the incidence rate of TF and
hospital readmissions.
Methods
The study protocol [9] and primary findings [7] have
been published previously.
The BACE trial
The BACE trial was an investigator-initiated multicentre
randomized (1:1) double-blind placebo-controlled trial,
evaluating the effectiveness and safety of azithromycin,
initiated and uploaded (500 mg once a day for 3 days)
within 48-h of hospital admission for a severe infectious
AECOPD on top of a standardized acute treatment of
systemic corticosteroids and antibiotics (Additional file 1:
Table S1), and subsequently administered (250 mg every
2 days) for a prolonged period of 3 months (i.e., 90 days).
Patients were followed-up for 6 months thereafter. The
study consisted of 3 visits during hospitalization of the
index event: randomization (day 1), start of maintenance
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dose (day 4) and day of discharge (day X, at the investi-
gator’s discretion). After discharge, patients were
followed at the out-patient department at 1 month after
discharge (day X + 28), end of intervention (day 90) and
end of follow-up (day 270). Telephone calls were sched-
uled bimonthly (day 150 and day 210) between day 90
and day 270.
Patients were monitored for the primary endpoint, TF
within 3 months, at day 4, day X, day X + 28 and day 90.
TF was defined as the composite of (1) TI with systemic
corticosteroids and/or antibiotics for respiratory reasons,
(2) SH including transfer to the intensive care unit
(ICU) and hospital readmissions for respiratory reasons
or (3) all-cause mortality (Additional file 1: Table S2).
All patient characteristics were obtained at hospital ad-
mission (baseline), except for the spirometry values
which were obtained at day X.
The BACE trial was approved by the Commissie
Medische Ethiek UZ-KU Leuven (central ethics com-
mittee, ML10232). Written informed consent was ob-
tained from all participants.
Patients
The patient population had an established diagnosis of
COPD, a current or past smoking history of ≥10 pack-
years and ≥ 1 exacerbation treated with systemic cortico-
steroids and/or antibiotics in the previous year. The
main exclusion criteria were contraindications to azi-
thromycin, respiratory insufficiency requiring mec-
hanical or non-invasive ventilation at the time of
randomization, high-dose systemic corticosteroid use (>
4 mg methylprednisolone/day) for ≥2 months and the
use of macrolide antibiotics for ≥2 weeks preceding in-
clusion. A full list of exclusion criteria is provided in
Additional file 1: Table S3.
Statistical analyses
All post-hoc analyses were assessed in the intention-to-
treat population (n = 301), and were performed using R
v3.1.0 (R Core Team, Vienna, Austria) and SAS software
v9.4 (SAS Institute, Cary, NC, USA). Count data of TF
were analysed by deconstructing TF into exclusive hier-
archical subcomponents based on severity (for TF: mor-
tality > SH > TI; for SH: transfer to the ICU > hospital
readmission). TI was termed a moderate, and SH and
mortality a severe event. The incidence rates and rate ra-
tio’s (RR) were evaluated using a generalized linear
model for a Poisson distribution at day X, day 90, and
day 270, as well as the post discharge period between
day X and day 90, with treatment as factor and log-
transformed exposure time as offset. In order to obtain
the estimated incidence during 90 and 270 days, the esti-
mated daily rates were multiplied by 90 and 270, re-
spectively. For day X and the post discharge period, the
daily rates were multiplied by the median hospital (6
days) and post-hospital (83 days) time. The incidence
rates should be interpreted with caution as model as-
sumptions were not entirely met, particularly at day 270.
To assess whether the intervention’s effect on the total
number of TFs and hospital readmissions within 3
months varied according to 9 pre-specified baseline pa-
tient characteristics, Poisson regression models were
used with log-transformed time in the study as offset
and treatment, subgroup and their interaction as factors
in the model. In these subgroup analyses, TF was de-
fined the composite of the individual subcomponents
and hospital readmission included readmissions result-
ing in ICU transfer or mortality. For CRP and blood
eosinophil count at admission, the analysis was addition-
ally stratified for treatment with systemic corticosteroids
prior to hospital admission to control for potential con-
founding [10].
Further analyses were performed for 4 subgroups
based on continuous variables (age, CRP, FEV1 and
blood eosinophil count), in which the continuous vari-
able was included in the model as a restricted cubic
spline to allow for any type of association with the
outcome.
All tests were two-sided and assessed at a significance
level of 5%. Due to exploratory nature of the analyses,
no adjustments were made to the significance level to
account for multiple testing.
Results
Patients
The present recurrent-event analyses included the
intention-to-treat population reported in the primary
time-to-first event analyses [7]. The key baseline charac-
teristics of the 301 patients, randomized to azithromycin
(n = 147) or placebo (n = 154), are summarized in
Table 1. The extended version is available in the Add-
itional file 1: Table S4. There were no statistically signifi-
cant group differences.
Recurrent events
Within 3 months of randomization, a total of 248 TFs
occurred: 106 in the azithromycin versus 142 in the pla-
cebo group (Table 2), resulting in a significant reduction
of 24% (RR = 0.76, 95%CI 0.59;0.98, p = 0.031) (Fig. 1a).
When decomposing TF in its exclusive hierarchical sub-
components, there was a nominal decrease in all-cause
mortality (RR = 0.61, 95%CI 0.13;2.48, p = 0.498), a sta-
tistically significant reduction of 50% in SH in favour of
azithromycin over placebo (RR = 0.50, 95%CI 0.30;0.81,
p = 0.006) (Fig. 1b) and no difference in TI (RR = 0.90;
95%CI 0.67;1.22, p = 0.508). All benefits were lost 6
months after treatment withdrawal, however, SH
remained considerably reduced (RR = 0.75, 95% CI 0.56;
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1.00, p = 0.053). 47 TFs (19%) occurred during the
hospitalization period of the index AECOPD and were
mainly moderate events: 18 in the azithromycin versus
24 in the placebo group (RR = 0.83, 95%CI 0.44;1.52, p =
0.544) (Fig. 1b). 201 TFs (81%) occurred during the
post-discharge period while on study medication (3-
month maximum) and consisted of 64% moderate (n =
128; 62 in the azithromycin versus 66 in the placebo






Age – years 66 ± 9 67 ± 10
Female sex – no. (%) 66 (45) 66 (43)
BMI – kg/m2 24.5 ± 5.9 25.1 ± 6.5
Comorbidity
Charlson comorbidity index 4 [3–5] 4 [3–5]
Lung disease
mMRC dyspnea score 4 [2–4] 4 [2–4]
Pre-bronchodilator FEV1 – L 0.90 [0.69–1.23] 0.95 [0.71–1.36]
Pre-bronchodilator FEV1 – % pred. 36.0 [26.3–53.8] 38.5 [29.0–52.0]
Pre-bronchodilator FEV1/FVC – % 40.3 [33.6–48.0] 45.0 [37.0–52.8]
GOLD stage – no. (%)a
A 0 (0) 1 (1)
B 26 (18) 30 (20)
C 1 (1) 2 (1)
D 120 (82) 121 (79)
Current smoker – no. (%) 63 (43) 65 (42)
Smoking history – pack-years 44 [37–50] 43 [35–50]
Inhaled therapy for COPD – no. (%)
LABA 136 (93) 145 (94)
LAMA 118 (80) 123 (80)
Inhaled corticosteroids 118 (80) 123 (80)
SABA 108 (73) 109 (71)
Admission presentation
GP intervention prior to admission – no. (%)
Systemic corticosteroids 48 (33) 37 (24)
Antibiotics 50 (34) 54 (35)
Laboratory
C-reactive protein (mg/L) 14.2 [3.5–61.4] 21.6 [4.5–59.6]
Leucocytes (× 109/L) 10.95 [9.00–13.89] 9.90 [8.20–13.70]
Neutrophils (×109/L) 8.20 [6.00–11.20] 7.70 [5.60–11.20]
Eosinophils (× 109/L) 0.06 [0.00–0.20] 0.07 [0.00–0.20]
Standardized acute treatment
Received – no. (%) 134 (91) 141 (92)
Received antibiotic – no. (%) 145 (99) 152 (99)
Pathogen susceptible to antibiotic b − no. (%) 136 (94) 144 (95)
Data are presented as either no. (%), mean ± SD or median [Q1-Q3 interquartile range]
Abbreviations: COPD Chronic obstructive pulmonary disease, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, GOLD Global initiative for chronic
Obstructive Lung Disease, guideline 2017, GP General practitioner, LABA Long-acting beta-agonist, LAMA Long-acting muscarinic antagonist, mMRC Modified
Medical Research Council questionnaire, SABA Short-acting beta-agonist
aGOLD stages are not taking the current hospital admission into consideration. bSusceptibility was determined based on the need for antibiotic upgrade prior to
discharge. Change or narrowing of the initial antibiotic based on proven bacterial cultures was considered good clinical practice
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group; RR = 0.95 (95%CI 0.67;1.34), p = 0.757) and 36%
severe events (n = 73; 25 in the azithromycin versus 48 in
the placebo group; RR = 0.52 (95%CI 0.32;0.84), p = 0.009).
When assessing the subcomponents of SH within 3
months (Fig. 1c), a non-significant 32% reduction in trans-
fer to the ICU (RR = 0.68, 95% CI 0.17;2.37, p = 0.546) was
observed, as well as a significant 53% reduction in hospital
readmissions (RR = 0.47, 95%CI 0.27;0.80; p = 0.007) after
hospital discharge of the index AECOPD.
Clinical subgroups
Subgroups based on 9 baseline covariates were assessed
for the incidence rate of TF and hospital readmissions
within 3months. While no statistically significant inter-
actions were observed between the intervention and any
of the subgroups for the incidence rate of TF (Table 3),
a significant interaction effect was observed between the
intervention and baseline CRP levels (pinteraction =
0.0349) for hospital readmissions. Patients with high
baseline CRP (> 50mg/L) treated with azithromycin had
significantly fewer hospital readmissions within 3
months, as compared to placebo (RR = 0.18, 95%CI 0.05;
0.60, p = 0.0053) (Table 4). Furthermore, a significant
interaction effect was observed between the intervention
and blood eosinophil count at hospital admission (pinter-
action = 0.0172). Patients with a baseline eosinophil count
< 300 cells/μL treated with azithromycin had signifi-
cantly fewer hospital readmissions within 3 months, as
compared to placebo (RR = 0.33, 95%CI 0.17;0.64, p =
0.0012) (Table 4). In contrast, patients with a baseline
eosinophil count > 300 cells/μL did not show a signifi-
cant effect on hospital readmission rate when treated
with azithromycin. Prior to hospital admission, 28%
(n = 85) of the randomized patients had received treat-
ment with systemic corticosteroids from their general
practitioner. In the non-pretreated patients, the observed
interaction between the intervention and both high CRP
and low blood eosinophil count for the incidence rate of
hospital readmissions remained statistically significant,
whereas in the pretreated patients no significant inter-
action was observed (Table 5).
From spline modelling, neither age, FEV1 (Additional
file 1: Figure S1), CRP nor blood eosinophil count (Fig. 2)
were significantly associated with the incidence rate of
TF or hospital readmissions. Notably, a p-value of 0.094
was observed for the interaction between blood eosino-
phil count at hospital admission and the incidence rate
of hospital readmissions within 3 months.
Discussion
The BACE trial was an investigator-initiated, random-
ized, double-blind, placebo-controlled trial evaluating a
3-month intervention with low-dose azithromycin, initi-
ated at the onset of a severe infectious AECOPD requir-
ing hospitalization. Although formally negative on the
composite primary endpoint (TF rate within 3months,
p = 0.0526), secondary time-to-first event analyses dem-
onstrated a significant 21 and 52% reduction in the rate
of TI and SH for respiratory reasons, respectively [7].
The present post-hoc analyses were performed to further
elucidate the intervention’s effect on recurrent events, in
particular hospital readmissions, and demonstrate that
azithromycin reduces the TF rate within 3 months of a
severe AECOPD by preventing subsequent hospital
readmissions with more than 50%.
COPD is a chronic disease, typically characterized by
recurrent exacerbations as the patient’s condition pro-
gressively deteriorates [11]. Severe exacerbations requir-
ing hospitalization are the number one contributor to
the overall burden and cost of the disease [5], warranting
targeted interventions to reduce these readmissions. In
the BACE trial, first events accounted for only 63% of





a) Number of first events Day 90 Day 270 Day 90 Day 270
Treatment failure 69 112 86 119
b) Number of recurrent events Day X Day 90 Day 270 Day X Day 90 Day 270
Treatment failure 19 106 306 28 142 322
Treatment intensification 18 80 217 24 90 206
Step-up in hospital care 0 23 82 2 47 107
Transfer to the ICU 0 4 13 2 6 15
Hospital readmission – 19 69 – 41 92
Mortality 1 3 7 2 5 9
Number of (a) first and (b) recurrent events of the primary composite endpoint, treatment failure, and its 3 exclusive subcomponents: treatment intensification,
step-up in hospital care (comprised of transfer to the ICU and hospital readmissions) and mortality prior to hospital discharge (day X, median: 6 [Q1-Q3
interquartile range: 4–8] days), within 90 and 270 days
day x, day of discharge, at the investigator’s discretion; day 90, end of intervention; day 270, end of follow-up
Abbreviations: ICU Intensive care unit
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the total number of TFs within 3 months. Though con-
ventionally applied, restricting the efficacy analyses to
first events would therefore incompletely represent the
intervention’s effect on the patient’s overall burden of
disease. Moreover, as time-to- first TF was defined as a
composite endpoint, with no hierarchy among the
Fig. 1 Incidence rate and rate ratio calculations prior to hospital discharge (day X, median: 6 [Q1-Q3 interquartile range: 4–8] days), within 90 and
270 days of a the primary composite endpoint, treatment failure, b its 3 exclusive subcomponents: treatment intensification, step-up in hospital
care and mortality, and c step-up in hospital care’s 2 exclusive subcomponents: transfer to the ICU and hospital readmissions. Abbreviations: ICU,
intensive care unit. Note: day x, day of discharge, at the investigator’s discretion; day 90, end of intervention; day 270, end of follow-up; *,
indicates significant difference
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different subcomponents, 98% of TFs were first captured
by TI even though they were subsequently accompanied
by SH or mortality. To provide insight into the true
components of TF, the present analyses focus on the ex-
clusive hierarchical subcomponents ranked by severity
(mortality > transfer to ICU > hospital readmission > TI
with systemic corticosteroids and/or antibiotics). In
doing so, we demonstrated that azithromycin reduces
the incidence rate of TF at 3 months mainly by reducing
subsequent hospital readmissions with 53%, while a clin-
ically relevant though statistically not significant 32% re-
duction in the transfers to the ICU was also observed.
Conversely, we found that azithromycin did not affect
the overall incidence rate of moderate events (i.e., treat-
ment intensification not resulting in hospital admission,
transfer to ICU or mortality), which – in part – could
account for the lack of statistically significant differences
in quality of life and symptom assessment scores ob-
served in the BACE trial [7]. When compiled, the BACE
trial results substantiate previous findings suggesting azi-
thromycin may be most effective in preventing severe
AECOPD requiring hospitalization [12–14]. Azithromy-
cin appears to modify the severity of new exacerbations,
so that this high risk subgroup may be less likely to
require hospitalization when they do experience new ex-
acerbations. The BACE trial is the first macrolide study
in COPD to identify this affordable therapeutic option as
a much desired intervention to safely reduce hospital
readmissions. Potential adverse effects related to the
intervention were discussed previously [7]. No group dif-
ferences were observed in the number of SH, its exclu-
sive subcomponents (transfer to the ICU and hospital
readmissions) or mortality between treatment with-
drawal (day 90) and 6months of follow-up (day 270),
supporting earlier time-to-first event analysis findings
that prolongation of intake is needed to maintain azi-
thromycin’s clinical benefits. Notably, an increased num-
ber of TI in the azithromycin group compared to the
Table 3 Subgroup analyses of the incidence rate of treatment failure within 90 days, in the intention-to-treat population
low CRP: ≤50mg/L; high CRP: > 50 mg/L
Abbreviations: CRP C-reactive protein, GOLD Global initiative for chronic Obstructive Lung Disease, guideline 2017, ICS Inhaled corticosteroid
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placebo group underlies an increase in the number of
TF when withdrawing azithromycin.
In the BACE trial, azithromycin was uploaded within
48 h post emergency admission, as potential benefits
during the index event were hypothesized to contribute
to the overall effect on the primary endpoint. Prior to
hospital discharge, azithromycin tended to reduce the
incidence rate of TF within 6 days compared to placebo
(25% reduction, with a 17 and 45% reduction in TI and
all-cause mortality, respectively). These observations
were not statistically significant as the study remained
largely underpowered for any conclusions on potential
benefits during the index event. Several studies, however,
have demonstrated that bacterial eradication in the acute
phase may result in better long-term outcomes, includ-
ing readmission rates [15–17]. Future prospective ran-
domized placebo-controlled trials with azithromycin are
therefore highly encouraged to evaluate the added value
of azithromycin in the acute setting of a severe
AECOPD, in addition to a limited prolonged administra-
tion to prevent relapse. At this stage, it is up to the clin-
ician to decide when prolonged therapy with macrolides
is indicated. Based on the BACE trial findings, patients
with COPD suffering from severe infectious exacerba-
tions are at least a target subgroup that needs proper
consideration.
The treatment effect of azithromycin appeared to
differ according to baseline CRP levels at hospital ad-
mission for the index event. Serum CRP has been
identified as a relatively sensitive and specific bio-
marker to distinguish patients who require antibiotics
[18, 19], with previous studies showing that a cut-off
value of 50 mg/L for high CRP is most optimal to de-
termine antibiotic needs [20–22]. We observed a large
and statistically significant effect of azithromycin on
hospital readmissions within 3 months in patients with
high CRP at baseline (31% of the studied population).
This may suggest that the antibacterial effect of
Table 4 Subgroup analyses of the incidence rate of hospital readmissions within 90 days, in the intention-to-treat population
low CRP: ≤50mg/L; high CRP: > 50 mg/L
Abbreviations: CRP C-reactive protein, GOLD Global initiative for chronic Obstructive Lung Disease, guideline 2017, ICS Inhaled corticosteroid
Vermeersch et al. Respiratory Research          (2019) 20:237 Page 8 of 12
azithromycin is the dominant mechanism, although
one may argue that all patients were already treated
with an effective antibiotic as part of the standardized
treatment during the index event. These findings
complement the observed 23% significant reduction in
the total days of antibiotic use within 3 months in the
azithromycin group when compared to placebo (a
pre-specified secondary endpoint of the main analysis,
p < 0.0001) [7]. Similarly, however, azithromycin was
found to be more effective in patients with absence of
blood eosinophilia at baseline, which corroborates
previous findings that high eosinophilia is a good
marker for the need of systemic corticosteroids [23].
This observation is biologically plausible, since macro-
lides have been shown to be effective in neutrophilic
chronic airway diseases and might be due to anti-
inflammatory and immunomodulatory effects in
addition to azithromycin’s antibiotic properties. Al-
though it is tempting to speculate that in AECOPD
with high blood eosinophilia azithromycin has no
added value, such biomarker guided treatment is
needing prospective studies before broad implementa-
tion can be recommended. It is currently unknown to
what degree azithromycin’s antimicrobial and anti-
inflammatory properties contribute to the compiled
BACE trial findings. As long as we have no macro-
lides available that are completely stripped of their
antibiotic properties, any further understanding of the
mechanism leading to its clinical benefits will be
influenced by this dual mode of action.
Through continuous spline modelling, neither age,
FEV1, CRP nor blood eosinophil count could be identified
as possible predictors of azithromycin response, deter-
mined from the incidence rate of TF and hospital read-
missions within 3months. However, we did observe a
trend for a negative association between blood eosinophil
count at hospital admission for a severe AECOPD and the
incidence rate of hospital readmissions within 3months in
patients treated with azithromycin.
The findings of the present study must be inter-
preted in the context of several potential limitations.
Most importantly, this is a post-hoc analysis of a trial
which was underpowered for the assessment of the
primary endpoint (p = 0.0526) due to early termin-
ation for slow recruitment. Not observing significant
interactions between any of the examined baseline
variables and the treatment effect of azithromycin
may therefore have been the result of type II errors.
Likewise, significant associations obtained from the
subgroup analyses may have resulted from an inflated
Table 5 Subgroup analyses of the incidence rate of (a) treatment failure (upper panels) and (b) hospital readmissions (lower panels)
within 90 days, in the intention-to-treat population, stratified for treatment with systemic corticosteroids prior to hospital admission
low CRP: ≤50mg/L; high CRP: > 50 mg/L, pretreated patients (panels left), non-pretreated patients (panels right)
Abbreviations: CRP C-reactive protein
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type I error rate, as multiple analyses were performed
simultaneously. Furthermore, a cautious interpretation
of the findings at day 270 is warranted as not all
model assumptions could be met. Prospective and ad-
equately powered clinical trials are therefore needed
to verify our hypothesis-generating findings. Second,
while TF (as well as each of its subcomponents) al-
lows for a continuous risk exposure during the
hospitalization period of the index exacerbation and
the post discharge period, a possible difference in ex-
posed risk was not accounted for when calculating
the incidence rates. Finally, although studies in COPD
have examined thresholds for blood eosinophil counts
and CRP levels, it has not yet been defined which
measurement – on a continuous rather than a dichot-
omous scale – is most appropriate to predict treat-
ment response as a biomarker.
Conclusion
In conclusion, a 3-month intervention with low-dose
azithromycin for severe infectious AECOPD requiring
hospitalization appears to reduce the rate of treatment
failure within 3months mainly by preventing subsequent
hospital readmissions. This complements the BACE tri-
al’s main finding that azithromycin may be a promising
and cost-saving therapy for a subgroup of patients with
the highest unmet needs. Although rigorous prospective
studies are required, the present findings also suggest a
potential role for CRP and blood eosinophil count at ad-
mission in guiding azithromycin therapy in patients with
a severe AECOPD.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12931-019-1208-6.
Additional file 1: Table S1. Standardized treatment for an acute COPD
exacerbation requiring hospitalization. Table S2. Definition of the
composite primary endpoint, treatment failure (TF). Table S3. Full list of
exclusion criteria. Table S4. Baseline patient characteristics. Figure S1.
Incidence rate of TF and hospital readmissions within 3 months by age
and pre-bronchodilator FEV1.
Abbreviations
AECOPD: Acute exacerbation of chronic obstructive pulmonary disease;
BACE: Belgian trial with azithromycin for COPD exacerbations requiring
hospitalization; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive
protein; FEV1: Forced expiratory volume in 1 s; ICU: Intensive care unit;
RCT: Randomized controlled trial; RR: Rate ratio; SH: Step-up in hospital care;
TF: Treatment failure; TI: Treatment intensification
Acknowledgements
We would like to thank the Flemish Government Agency for Innovation by
Science and Technology (IWT) for funding the BACE trial through the
Fig. 2 Incidence rate of treatment failure (panels left) and hospital readmissions (panels right) within 3 month by a CRP, and b blood eosinophil
count at day of admission. Abbreviations: CRP, C-reactive protein; TF, treatment failure. Note: Plots are depicted from the 10th to 90th percentile
of the respective covariates
Vermeersch et al. Respiratory Research          (2019) 20:237 Page 10 of 12
Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit
(TBM) program: IWT-TBM number 130233. The trial was also approved and
supported by the Belgian Thoracic Society (BVP-SBP) which provided logistic
support for the organization of the investigator meetings. Financial support
for study logistics was also received from TEVA, Belgium. Neither the IWT,
BVP-SBP nor TEVA were involved in the study design, in the collection, ana-
lysis and interpretation of data, in the writing of the manuscript, or in the de-
cision to submit the manuscript for publication.
We thank the BACE trial patients for their participation, and the BACE trial
investigators and supporting staff for their contributions in the Consortium:
Vincent Ninane (CHU St.-Pierre – Brussel), Joseph Aumann (Jessa ziekenhuis –
Hasselt), Ingel K Demedts (AZ Delta – Roeselare-Menen), Hans Slabbynck
(ZNA Middelheim – Antwerpen), Eric Marchand (CHU-UCL Namur – Yvoir),
Christel Haenebalcke (AZ St-Jan ziekenhuis – Brugge), Rudi Peché (CHU de
Charleroi – Charleroi), Guy G Brusselle (UZ Gent - Gent), Walter Vincken (UZ
Brussel – Brussel), Jean-Louis Corhay (CHU de Liège – Luik), Michiel Haerens
(AZ Groeninge – Kortrijk), Antoine Fremault (Grand Hôpital de Charleroi –
Charleroi), Tine Lauwerier (Imelda ziekenhuis – Bonheiden), Alix Debrock (St-
Augustinus ziekenhuis – Antwerpen), Jan Lamont (Maria Middelares zieken-
huis – Gent), Geert Tits (St-Andriesziekenhuis – Tielt), Paul Jordens (Onze-
Lieve-Vrouwziekenhuis – Aalst), Alain Delobbe (Clinique Reine Astrid – Mal-
medy), Jean-Benoît Martinot (Clinique Ste.-Elisabeth – Namur).
Notation of prior abstract presentation and publication
Data were presented at the American Thoracic Society International
Conference, May 2019 – Dallas (USA). Janssens W, Vermeersch K, Troosters T,
Brusselle GG. Effect of a 3-month low-dose azithromycin intervention for
COPD exacerbations requiring hospitalization on subsequent respiratory
events and mortality – The BACE trial. Am J Respir Crit Care Med 2019;
199:A1115.
Authors’ contributions
WJ, KV, IG, NC, AB and KB were involved in the design and data extraction of
the study. The BACE trial dataset consists of data which were gathered by
study personnel at the participating hospitals within the Consortium,
overseen by the local investigator. The statistical analyses were performed by
KV and AB. The first and final draft were written by KV and WJ, and revised
on the basis of input from the other authors and the BACE trial Steering
Committee. All the authors contributed to the interpretation of the data and
critical review of the manuscript, and approved the submission of the final
draft for publication. WJ is guarantor of the manuscript.
Funding
This work is part of The Belgian trial with Azithromycin for acute COPD
Exacerbations requiring hospitalizations (BACE trial) which is funded by the
Flemish Government Agency for Innovation by Science and Technology
(IWT, grant number: IWT-TBM130233). The IWT was not involved in the study
design, in the collection, analysis, and interpretation of data, in the writing of
the manuscript, or in the decision to submit the manuscript for publication.
Availability of data and materials
All data generated or analysed during this study are included in this
published article, and its supplementary information file.
Ethics approval and consent to participate
In the BACE trial, written informed consent was obtained from all
participants. The study was approved by the competent authorities, the
central (Commissie Medische Ethiek UZ-KU Leuven, ML10232) and local eth-




-KV is supported as a doctoral candidate by the Flemish Government Agency
for Innovation by Science and Technology (Belgium).
-AB’s institute received consultancy fees from Boehringer-Ingelheim and UCB
Pharma.
-KB’s institute received consultancy fees from Boehringer-Ingelheim and UCB
Pharma.
-IG has nothing to disclose.
-NC has nothing to disclose.
-MG has nothing to disclose.
-JA has nothing to disclose.
-IKD has nothing to disclose.
-JLC has received speaker and consultancy fees from Boehringer-Ingelheim,
AstraZeneca, Novartis, Chiesi and GlaxoSmithKline.
-EM has, within the last 5 years, received honoraria for lectures from
Boehringer-Ingelheim, Chiesi and Novartis; he is a member of advisory
boards for AstraZeneca, Chiesi, Boehringer-Ingelheim and Novartis.
-HS has received consultancy fees from Boehringer-Ingelheim and
GlaxoSmithKline.
-CH has received speaker and consultancy fees from Boehringer-Ingelheim,
Chiesi, AstraZeneca, GlaxoSmithKline and Novartis.
-SV has nothing to disclose.
-GMV has nothing to disclose.
-TT is vice president of the European Respiratory Society (2018–2019). His
institute received speaker and consultancy fees from Boehringer-Ingelheim,
AstraZeneca and Chiesi.
-VN has received speaker and consultancy fees from Boehringer-Ingelheim,
AstraZeneca, Novartis, MSD, GlaxoSmithKline and Chiesi.
-GB has, within the last 5 years, received honoraria for lectures from
AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer,
Teva, UCB Pharma and Zambon; he is a member of advisory boards for
AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regen-
eron and Teva.
-WJ is supported as a senior clinical researcher by the Fund for Scientific
Research Flanders (Belgium); and has received research funding, speaker and
consultancy fees from Boehringer-Ingelheim, AstraZeneca, Novartis, Chiesi
and GlaxoSmithKline. WJ is co-founder of ArtIQ.
Author details
1Laboratory of Respiratory Diseases, Department of Chronic Diseases,
Metabolism and Ageing, KU Leuven, Herestraat 49, O&NI, box 706, B-3000
Leuven, Belgium. 2Department of Respiratory Diseases, University Hospitals
Leuven, B-3000 Leuven, Belgium. 3I-BioStat, KU Leuven, B-3000 Leuven,
Belgium. 4Universiteit Hasselt, B-3500 Hasselt, Belgium. 5Department of
Pneumology, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de
Bruxelles, B-1000 Brussels, Belgium. 6Department of Pneumology, Jessa
Ziekenhuis, B-3500 Hasselt, Belgium. 7Department of Respiratory Medicine,
AZ Delta Roeselare-Menen, B-8800 Roeselare, Belgium. 8Department of
Pneumology, Centre Hospitalier Universitaire, site Sart-Tilman, B-4000 Liège,
Belgium. 9Department of Pneumology, CHU-UCL-Namur, site Mont-Godinne,
B-5530 Yvoir, Belgium. 10Faculty of Medicine, NARILIS, Laboratory of
Respiratory Physiology, University of Namur, B-5000 Namur, Belgium.
11Department of Respiratory Medicine, ZNA Middelheim, B-2020 Antwerpen,
Belgium. 12Department of Pneumology, AZ Sint-Jan, B-8000
Brugge-Oostende, Belgium. 13Department of Respiratory Medicine, Ghent
University Hospital, B-9000 Ghent, Belgium. 14Department of Rehabilitation
Sciences, Faculty of Kinesiology and Rehabilitation Sciences, KU Leuven,
Leuven, Belgium.
Received: 16 August 2019 Accepted: 9 October 2019
References
1. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA.
Effect of exacerbation on quality of life in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med.
2012;157(5):1418–22.
2. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations
on pulmonary function, health status and clinical outcomes. Int J Chron
Obs Pulmon Dis. 2009;4:245–51.
3. Wedzicha JA, Donaldson GC. Natural history of successive COPD
exacerbations. Thorax. 2012;67(11):935–6.
4. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global
strategy for the diagnosis, management, and prevention of COPD, 2018
report. 2018. Available from: http://goldcopd.org
5. Halpin DMG, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of
severe exacerbations of COPD: a review of the evidence. Int J COPD. 2017;
12:2891–908.
6. Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27(3):1–9.
Vermeersch et al. Respiratory Research          (2019) 20:237 Page 11 of 12
7. Vermeersch K, Gabrovska M, Aumann J, et al. Azithromycin during acute
COPD exacerbations requiring hospitalization (BACE): a multicentre,
randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care
Med. 2019; In Press.
8. Rauch G, Kieser M, Binder H, Bayes-Genis A, Jahn-Eimermacher A. Time-to-
first-event versus recurrent-event analysis: points to consider for selecting a
meaningful analysis strategy in clinical trials with composite endpoints. Clin
Res Cardiol. 2018;107(5):437–43.
9. Vermeersch K, Gabrovska M, Deslypere G, et al. The Belgian trial with
azithromycin for acute COPD exacerbations requiring hospitalization: an
investigator-initiated study protocol for a multicenter, randomized, double-
blind, placebo-controlled trial. Int J COPD. 2016;11(1):687–96.
10. Müller B, Peri G, Doni A, et al. High circulating levels of the IL-1 type II
decoy receptor in critically ill patients with sepsis: association of high
decoy receptor levels with glucocorticoid administration. J Leukoc Biol.
2002;72(4):643–9.
11. Rennard SI, Farmer SG. Exacerbations and progression of disease in
asthma and chronic obstructive pulmonary disease. Proc Am Thorac
Soc. 2004;1(2):88–92.
12. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive
pulmonary disease exacerbation reduction in response to daily azithromycin
therapy. Am J Respir Crit Care Med. 2014;189(12):1503–8.
13. Krishnan JK, Voelker H, Connett JE, et al. Effect of daily azithromycin therapy
and adherence on readmission risk in COPD. Eur Respir J. 2019;53(3). https://
doi.org/10.1183/13993003.01377-2018.
14. Pomares X, Montón C, Bullich M, et al. Clinical and safety outcomes of long-
term azithromycin therapy in severe COPD beyond the first year of
treatment. Chest. 2018;153(5):1125–33.
15. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/
clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL
results. Eur Respir J. 2012;40(1):17–27.
16. Irani AP, Hicks LS. Reducing the readmission burden of COPD: a focused
review of recent interventions. Curr Emerg Hosp Med Rep. 2014;2(3):172–81.
17. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK.
Antibiotic therapy and treatment failure in patients hospitalized for acute
exacerbations of chronic obstructive pulmonary disease. JAMA - J Am Med
Assoc. 2010;303(20):2035–42.
18. Brightling CE. Biomarkers that predict and guide therapy for
exacerbations of chronic obstructive pulmonary disease. Ann Am
Thorac Soc. 2013;10:S214–9.
19. Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in
hospitalized adult patients with community-acquired pneumonia or
exacerbation of asthma or COPD. Chest. 2011;139(6):1410–8.
20. Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in
acute exacerbations of COPD admitted to hospital. Eur Respir J. 2019;53(5).
https://doi.org/10.1183/13993003.02014-2018.
21. Stolz D, Christ-Crain M, Gencay MM, et al. Diagnostic value of signs,
symptoms and laboratory values in lower respiratory tract infection. Swiss
Med Wkly. 2006;136(27–28):434–40.
22. Daniels JMA, Snijders D, De Graaff CS, Vlaspolder F, Jansen HM, Boersma
WG. Antibiotics in addition to systemic corticosteroids for acute
exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit
Care Med. 2010;181(2):150–7.
23. Bafadhel M, Mckenna S, Terry S, et al. Blood Eosinophils to direct
corticosteroid treatment of exacerbations of chronic obstructive pulmonary
disease. Am J Respir Crit Care Med. 2012;186(1):48–55.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Vermeersch et al. Respiratory Research          (2019) 20:237 Page 12 of 12
